VGX International

Last updated: 13.02.2014

Address: 1787 Sentry Parkway West Building 18, Suite 400 Blue Bell, PA 19422-2200

Tel: 82 267.440.4200

Web: http://www.inovio.com/

Company description

VGX™ Pharmaceuticals is a leading biopharmaceutical company with strong product candidates for the treatment of infectious diseases, including HIV, as well as cancer and inflammatory diseases. The Company’s clinical development programs include PENNVAX™-B, a DNA vaccine for the prevention of HIV in Phase I clinical trials; VGX-1027, a small molecule drug for inflammatory diseases in Phase I clinical trials; VGX-3100, a DNA therapetic vaccine for cervical cancer in Phase I clinical trials; and CELLECTRA® delivery device in Phase I clinical trials.In addition, VGX has filed INDs for VGX-3200 and VGX-3400 for cancer cachexia and avian influenza, respectively.The lead therapeutic programs in infectious diseases and oncology are well complemented by a strong research pipeline of next-generation DNA vaccines. VGX’s proprietary content, coupled with a patented DNA delivery system (CELLECTRA® electroporation), and acess to state-of-the-art cGMP plasmid Manufacturing capabilities form the Company’s DNA Vaccines and Therapies Platform, which gives VGX a unique position relative to its peers with DNA vaccines and therapeutics programs.

Interviews

Related

We use cookies to ensure that we give you the best experience on our site. For more info click here